157 related articles for article (PubMed ID: 9519149)
21. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.
Heinemann L; Sinha K; Weyer C; Loftager M; Hirschberger S; Heise T
Diabet Med; 1999 Apr; 16(4):332-8. PubMed ID: 10220208
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.
Jacobsen LV; Søgaard B; Riis A
Eur J Clin Pharmacol; 2000 Aug; 56(5):399-403. PubMed ID: 11009049
[TBL] [Abstract][Full Text] [Related]
23. Hybrid insulin cocrystals for controlled release delivery.
Brader ML; Sukumar M; Pekar AH; McClellan DS; Chance RE; Flora DB; Cox AL; Irwin L; Myers SR
Nat Biotechnol; 2002 Aug; 20(8):800-4. PubMed ID: 12134168
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes.
Hompesch M; Ocheltree SM; Wondmagegnehu ET; Morrow LA; Kollmeier AP; Campaigne BN; Jacober SJ
Curr Med Res Opin; 2009 Nov; 25(11):2679-87. PubMed ID: 19761358
[TBL] [Abstract][Full Text] [Related]
25. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
26. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control.
Trautmann ME
Horm Metab Res; 1994 Dec; 26(12):588-90. PubMed ID: 7705764
[TBL] [Abstract][Full Text] [Related]
27. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.
Jehle PM; Micheler C; Jehle DR; Breitig D; Boehm BO
Lancet; 1999 Nov; 354(9190):1604-7. PubMed ID: 10560676
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
Luzio SD; Beck P; Owens DR
Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection.
Sonaje K; Lin KJ; Wey SP; Lin CK; Yeh TH; Nguyen HN; Hsu CW; Yen TC; Juang JH; Sung HW
Biomaterials; 2010 Sep; 31(26):6849-58. PubMed ID: 20619787
[TBL] [Abstract][Full Text] [Related]
30. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
[TBL] [Abstract][Full Text] [Related]
31. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.
Owens DR; Bolli GB
Diabetes Technol Ther; 2008 Oct; 10(5):333-49. PubMed ID: 18715209
[TBL] [Abstract][Full Text] [Related]
32. Blood glucose profiles in diabetic rodents using different insulin preparations.
Schneider S; Weber R; Luippold G
Arzneimittelforschung; 2004; 54(12):842-6. PubMed ID: 15646368
[TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.
Home PD
Diabetes Obes Metab; 2012 Sep; 14(9):780-8. PubMed ID: 22321739
[TBL] [Abstract][Full Text] [Related]
34. [Action profile of human ultralente insulin compared with human NPH-insulin].
Starke AA; Heinemann L; Hohmann A; Berger M
Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061
[TBL] [Abstract][Full Text] [Related]
35. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
36. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
Heinemann L; Heise T; Wahl LC; Trautmann ME; Ampudia J; Starke AA; Berger M
Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
[TBL] [Abstract][Full Text] [Related]
37. Enhanced hypoglycemic activity following intratracheal administration of insulin microcrystal suspension with injection adjuvant.
Lee HK; Kwon JH; Park SH; Kim CW
Biosci Biotechnol Biochem; 2006 Apr; 70(4):1003-5. PubMed ID: 16636470
[TBL] [Abstract][Full Text] [Related]
38. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
[TBL] [Abstract][Full Text] [Related]
39. [A study of the absorption of NPH insulin administered into subcutaneous tissue: in vitro study of the mechanism of insulin release from NPH insulin crystal].
Yanagisawa K
Hokkaido Igaku Zasshi; 1992 Jan; 67(1):81-8. PubMed ID: 1559663
[TBL] [Abstract][Full Text] [Related]
40. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
